Intolerance to additives.

C. Collins-Williams

1983-08-01

Abstract:

What problem does this paper attempt to address?

Transient segmental asynergy of the left ventricle of patients with various clinical manifestations possibly unrelated to the coronary artery disease.

K. Iga,K. Hori,Katuji Kitaguchi,T. Matsumura,H. Gen,Go Tomonaga,T. Tamamura

DOI: https://doi.org/10.1253/JCJ.55.1061

1991-11-20

Japanese Circulation Journal

Abstract:Eight cases of transient reversible segmental asynergy of the left ventricle thought not to be related to coronary artery lesions are reported. Three cases were associated with inflammatory reactions of unknown origin, and one each with lactic acidosis, abdominal surgery, hypoglycemia, tetanus and pneumonia. None of the patients had symptoms suggestive of ischemic heart disease before or after these episodes. Electrocardiograms before these episodes were all normal. Two-dimensional echocardiography was performed to evaluate abnormal electrocardiograms. Coronary angiography was performed in 4 of 8 cases and was normal in all 4 cases; 2 done as emergencies and 2 non-emergencies. Two ergonovine tests were negative. Left ventricular wall motion abnormalities, present mainly at the apex of the left ventricle, returned to normal in 1 to 4 weeks. Giant negative T waves in the chest leads during this recovery period were characteristic electrocardiographic features and normalized in 6 weeks on average. We believe that these episodes were not related to ischemia due to coronary artery disease, but to some metabolic humoral factors. An excellent prognosis can be expected if these abnormal metabolic circumstances can be resolved.
Nectin-4 expression in primary breast cancer and associated clinical outcomes.

Arielle J Medford,Andrzej Niemierko,Rachel Occhiogrosso Abelman,Nicholas Haradhvala,Justine Knape,Laura Spring,Gad Getz,Aditya Bardia

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.570

IF: 45.3

2024-05-31

Journal of Clinical Oncology

Abstract:570 Background: Antibody-drug conjugates (ADC) selectively deliver chemotherapy to tumor cells expressing a target antigen. Currently approved ADCs in breast cancer target HER2 or Trop-2. Enfortumab vedotin, an ADC targeting Nectin-4, a cell adhesion molecule, is approved in advanced/metastatic urothelial cancer. This study evaluated the expression landscape of Nectin-4 in breast cancer and its association with clinical outcomes. Methods: Processed mRNAseq data was assessed for expression of the gene encoding Nectin-4 in primary breast cancer tissue and adjacent normal breast tissue from The Cancer Genome Atlas (TCGA), and normal tissue from the Genotype-Tissue Expression (GTEx) Project. Low gene expression was determined as <100 transcripts per million (TPM). TCGA samples had been annotated for putative copy-number alterations using GISTIC 2.0; genes with a score of 2 were marked as amplified. Multivariable Cox regression analysis was used to analyze the association of low vs medium/high gene expression with disease-free survival (DFS) and overall survival (OS), adjusting for age, stage, and subtype. Results: RNA-Seq data was available for 1086 patients with primary breast cancer, including known hormone receptor positive (HR+)/HER2- (n=530), HER2+ (n=112), and triple negative breast cancer (TNBC) (n=120). NECTIN4was amplified in 15% of cases (n=165): 15% (n=78) in HR+, 15% (n=17) in HER2+ and 21% (n=25) in TNBC. NECTIN4 expression was medium/high in 356 (33%) patients: 149 (28%) HR+/HER2- (median 77.8 TPM, IQR 50.1-116.5), 32 (29%) HER2+ (median 73.7 TPM, IQR 51.9-107.8), and 59 (49%) TNBC (median 99.7 TPM, IQR 57.8-148.3). Median expression in normal breast tissue was 47 TPM (TCGA) & 16.74 TPM (GTEx), and highest in normal skin at 205 TPM. In multivariable analysis, medium/high NECTIN4 expression was associated with worse OS (HR 1.96, 95% CI 1.32-2.99, p<0.001). As a continuous variable, increasing NECTIN4 expression levels were associated with worse OS. After correcting for age, stage and subtype, for each 10-unit increase in NECTIN4TPM, the risk of death increased by 5% (HR 1.0050, 95% CI 1.0028 - 1.0072, p < 0.001). Conclusions: NECTIN4 expression was higher in TNBC and associated with worse overall survival. The high expression level in normal skin possibly contributes to the cutaneous toxicity associated with enfortumab vedotin approval and requires careful consideration as ADCs targeting Nectin-4 are developed to target breast cancer.

oncology
Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes

Jean H Hoffman-Censits,Kara A Lombardo,Vamsi Parimi,Sonia Kamanda,Woonyoung Choi,Noah M Hahn,David J McConkey,Bridget M McGuire,Trinity J Bivalacqua,Max Kates,Andres Matoso

DOI: https://doi.org/10.1097/PAI.0000000000000938

2021-09-01

Abstract:The antibody-drug conjugate enfortumab-vedotin acts by targeting nectin-4, a protein that is nearly ubiquitously expressed in conventional urothelial cancer. However, expression of nectin-4 in morphologic variants of urothelial carcinoma and nonurothelial histotypes was unknown. Immunohistochemistry for nectin-4 using was performed on 169 patients including 83 with nonmuscle invasive bladder cancer and 86 patients with muscle invasive bladder cancer. Staining was scored for intensity (0 to 3) and extent (% positive cells) using the histological score system, where >15 was considered positive. Overall, 72/83 (87%) samples of nonmuscle invasive urothelial carcinoma were positive, including 29/30 (97%) noninvasive papillary urothelial carcinomas, 7/8 (87.5%) carcinomas in situ, 36/45 (80%) papillary urothelial carcinomas invading the lamina propria. Overall, 50/86 muscle invasive tumors were positive, including 15/22 (68.2%) urothelial carcinomas, 7/10 (70%) squamous cell carcinomas, 3/11 (28%) micropapillary tumors, 4/6 (66%) adenocarcinomas, 2/4 (50%) nested carcinomas, 5/8 (63%) plasmacytoid, 1/10 (10%) sarcomatoid carcinomas, and 0/15 (0%) small cell carcinomas. Whole transcriptome RNA sequencing revealed that compared with conventional urothelial carcinomas, most sarcomatoid carcinomas and all but 2 small cell carcinomas expressed very low levels of nectin-4 mRNA but expressed significant levels of either trop2 or ERBB2, which are the molecular targets of 2 other antibody-drug conjugates-sacituzumab gavitecan (trop2) or trastuzumab deruxtecan (ERBB2/HER2). In summary, our study demonstrates that there is heterogeneity of expression of nectin-4 in morphologic variants of urothelial cancer and nonurothelial histotypes, and suggests that testing expression of nectin-4 should be considered in morphologic variants or nonurothelial histotypes found to have lower expression.
Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas

Christoph Arolt,Moritz Meyer,Vanessa Ruesseler,Lisa Nachtsheim,Nora Wuerdemann,Thomas Dreyer,Stefan Gattenlöhner,Claus Wittekindt,Reinhard Buettner,Alexander Quaas,Jens Peter Klussmann

DOI: https://doi.org/10.1007/s00262-020-02551-6

Abstract:Salivary gland carcinomas (SGCs) are rare and can be subdivided into distinct entities, some of which confer a poor prognosis. As targets for effective systemic therapy are warranted, some studies investigated the role of immune-checkpoint proteins PD-L1 and CTLA-4 in SGC. Our study depicts the expression of lymphocyte activation gene 3 (LAG3) in a test cohort and a larger validation cohort, totaling 139 SGCs. LAG3 is expressed on tumor-infiltrating lymphocytes (TILs), mediates T cell exhaustion and is subject to numerous currently recruiting clinical studies. Overall, one-third of SGCs were infiltrated by LAG3-expressing TILs with a strikingly high concordance between the test cohort and the validation cohort (30% and 28.2%, respectively). In the validation cohort, entity-wise LAG3 expression frequencies were highly variable. The highest rates were observed in salivary duct carcinoma (SDC; 66.7%) and adenocarcinoma not otherwise specified (ANOS; 50.0%). We observed LAG3 expression on effector T cells and in smaller frequencies also on FOXP3- T helper cells and FOXP3+ Tregs. LAG3 expression significantly correlated with advanced nodal metastases, cytotoxic T cell infiltrate and TP53 mutations. In the group of adenoid cystic carcinomas, LAG3 expression was also associated with a shorter event-free survival (EFS). Tumors with TP53 nonsense mutations (TP53 null type) exhibited higher LAG3 frequencies and a shorter EFS compared to TP53 wild type. This is the first report of LAG3 expression in SGC, a promising target for immunotherapy. LAG3 blockage could be distinctly applicable for SDC and ANOS, two SGC types with a particularly poor outcome.
Nectin-4: A promising prognostic marker and therapeutic target in cancer

Shilpa Kuttikrishnan,Kirti S. Prabhu,Ummu Habeeba,Zahwa Mariyam,Queenie Fernandes,Mohsin Maqbool,Omar M. Khan,Ajaz A. Bhat,Shahab Uddin

DOI: https://doi.org/10.1016/bs.ircmb.2024.08.004

2024-09-14

International Review of Cell and Molecular Biology

Abstract:Nectin cell adhesion protein 4 (Nectin-4), a calcium-independent immunoglobulin-like protein, has garnered significant attention in oncology due to its pronounced overexpression in malignant tumors and absence in healthy adult tissues. Elevated levels of Nectin-4 have been implicated in the pathogenesis of various cancers, including lung, breast, and urothelial carcinomas. Notably, Nectin-4 has emerged as a promising serological marker for these malignancies, facilitating early diagnosis and monitoring of disease progression. The clinical relevance of Nectin-4 is underscored by the Food and Drug Administration's approval of enfortumab vedotin (EV), the first antibody-drug conjugate targeting this protein, for the treatment of urothelial carcinoma. Ongoing clinical trials are expanding the therapeutic applications of EV, highlighting the critical role of Nectin-4 in targeted cancer therapy. Furthermore, novel therapeutic agents targeting Nectin-4 are under investigation, offering potential new avenues for cancer treatment. Despite these advancements, the precise molecular mechanisms by which Nectin-4 influences carcinogenesis and tumor progression remain inadequately understood. Challenges such as therapy-related adverse effects and the development of drug resistance further complicate the clinical management of Nectin-4-associated cancers. This review investigates the molecular functions of Nectin-4, emphasizing its diagnostic and prognostic value in cancer. We also explore the landscape of novel drug discoveries targeting Nectin-4 and provide an overview of current clinical trials aimed at utilizing this marker for therapeutic interventions. By elucidating the multifaceted role of Nectin-4 in malignancies, this article aims to advance our understanding and improve the clinical outcomes for patients with Nectin-4 overexpressing tumors.

cell biology,biochemistry & molecular biology
Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate

Hanno M. Witte,Niklas Gebauer,Daniela Lappöhn,Vincent G. Umathum,Armin Riecke,Annette Arndt,Konrad Steinestel

DOI: https://doi.org/10.3390/cancers12040873

2020-04-03

Cancers

Abstract:Background: Malignant neoplasms of the salivary glands are rare, and therapeutic options are limited. Results from recently published studies indicate a possible use for checkpoint inhibition in a subset of patients, but there are no established criteria for programme cell death ligand 1 (PD-L1) scoring in salivary gland carcinomas (SGCs). Methods: In this retrospective study, we present a cohort of 94 SGC patients with full clinical follow-up. We included 41 adenoid cystic carcinomas (AdCC), 21 mucoepidermoid carcinomas (MEC), 16 acinic cell carcinomas (ACC), 12 adenocarcinomas, not otherwise specified (AC, NOS), 2 epithelial-myoepithelial carcinomas (EMC), one salivary duct carcinoma (SDC), and one carcinoma ex pleomorphic adenoma (CA ex PA). Subsequent histopathological analysis was performed with special emphasis on the composition of the immune cell infiltrate (B-/T-lymphocytes). We assessed PD-L1 (SP263) on full slides by established scoring criteria: tumor proportion score (TPS), combined positivity score (CPS) and immune cell (IC) score. Results: We identified significantly elevated CD3+, TP, CP, and IC scores in AC, NOS compared to AdCC, MEC, and ACC. CPS correlated with node-positive disease. Moreover, AC, NOS displayed IC scores of 2 or 3 in the majority (67%) of cases (p = 0.0031), and was associated with poor prognosis regarding progression-free (PFS) (p < 0.0001) and overall survival (OS) (p < 0.0001). CPS correlated with strong nuclear or null p53 staining in AC, NOS but not in other SGCs. Long-lasting partial remission could be achieved in one AC, NOS patient who received Pembrolizumab as third-line therapy. Conclusions: The current study is the first to investigate the use of established scoring criteria for PD-L1 expression in malignant salivary gland tumors. Our findings identify unique characteristics for AC, NOS among the family of SGCs, as it is associated with poor prognosis and might represent a valuable target for immune checkpoint inhibition.

oncology
Pneumovesicoscopic Correction of Primary Vesicoureteral Reflux (VUR) in Children. Our Experience

A. Marte,M. D. Sabatino,M. Borrelli,F. Nino,M. Prezioso,L. Pintozzi,P. Parmeggiani

DOI: https://doi.org/10.1055/s-0030-1262799

2010-10-15

European Journal of Pediatric Surgery

Abstract:Aim: Material and Methods: Results: Conclusion:
Targeted Therapeutic Strategies for Nectin-4 in Breast Cancer: Recent Advances and Future Prospects

Yufei Wang,Guangliang Li,Hanying Wang,Quan Qi,Xian Wang,Haiqi Lu

DOI: https://doi.org/10.1016/j.breast.2024.103838

2024-01-01

Abstract:Nectin-4 is a cell adhesion molecule which has gained more and more attention as a therapeutic target in cancer recently. Overexpression of Nectin-4 has been observed in various tumors, including breast cancer, and is associated with tumor progression. Enfortumab vedotin(EV)is an antibody-drug conjugate (ADC) targeting Nectin-4, which has been approved by FDA for the treatment of urothelial carcinoma. Notably, Nectin-4 was also investigated as a target for breast cancer in preclinical and clinical settings. Nectin-4-targeted approaches, such as ADCs, oncolytic viruses, photothermal therapy and immunotherapy, have shown promising results in early-phase clinical trials. These therapies offer novel strategies for delivering targeted treatments to Nectin-4-expressing cancer cells, enhancing treatment efficacy and minimizing off-target effects. In conclusion, this review aims to provide an overview of the latest advances in understanding the role of Nectin-4 in breast cancer and discuss the future development prospects of Nectin-4 targeted agents.
Expression of Neural Cell Adhesion Molecule in 49 Cases with Salivary Adenoid Cystic Carcinoma and Its Significance

金善恩,王可敬,赏金标,魏启春

IF: 4.501

2010-01-01

Journal of Oncology

Abstract:[Purpose]To investigate expression of neural cell adhesion molecule (NCAM) in salivary adenoid cystic carcinoma(SACC) and its clinical significance. [Methods] The expression of NCAM in 49 cases with SACC was detected by immunohistochemical technique. [Results] The positive rate of NCAM was 57.14%(28/49). NCAM expression was not related to gender, tumor site and staging. NCAM expressions in SACC tubular subtype and in solid subtype were significantly different (χ2=4.07,P=0.04). NCAM expression with neural invasion was significantly higher than that without neural invasion (P0.05). [Conclusion] The NCAM closely correlates to neural invasion in SACC. NCAM plays an important role in neural invasion of SACC.
Occurrence of NECTIN4 amplification in solid tumors and enfortumab vedotin response in metastatic urothelial cancer.

Niklas Klümper,Ngoc Khanh Tran,Stefanie Zschaebitz,Oliver Hahn,Friedemann Zengerling,Dora Nagy,Glen Kristiansen,Philipp Ivanyi,Camilla Marisa Grunewald,Christopher Darr,Katrin Schlack,Steffen Rausch,Manuel Ritter,Kerstin Junker,Arndt Hartmann,Viktor Grünwald,Michael Hölzel,Markus Eckstein

DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.673

IF: 45.3

2024-01-31

Journal of Clinical Oncology

Abstract:673 Background: The anti-NECTIN4 antibody-drug conjugate (ADC) enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet uncharacterized patient subset. NECTIN4 is located on chromosome 1q23.3, and 1q23.3 gains are frequent genomic events in mUC leading to NECTIN4 amplifications. Here, we aimed to evaluate the potential of NECTIN4 amplification as a genomic biomarker to predict EV response in patients with mUC. Methods: We established a NECTIN4-specific fluorescence in-situ hybridization (FISH) assay to assess NECTIN4 copy number variations (CNVs) in a multicenter EV-treated mUC patient cohort (UC-EV, N=77), and CNV data were correlated with membranous NECTIN4 protein expression (H-score) assessed via immunohistochemistry, EV treatment responses and outcomes. Next, we conducted a pan-cancer analysis of the The Cancer Genome Atlas (TCGA) datasets, comprising 10,712 patients across 32 cancer types, to investigate the relationship between NECTIN4 CNV, mRNA expression (RNAseq) and protein levels (RPPA) across entities. Results: In TCGA cohorts, NECTIN4 amplification occurs frequently across different solid cancer types, especially in 15-20% of bladder cancers (17% in TCGA-BLCA), as well as 5-10% in breast cancer (TCGA-BRCA) and lung adenocarcinoma (TCGA-LUAD). We confirmed the amplification frequency in our UC-EV cohort (18%). NECTIN4 amplification is significantly associated with both increased NECTIN4 mRNA expression (e.g., TCGA-BLCA, BRCA, LUAD) and membranous NECTIN4 protein expression (UC-EV), and represents a stable genomic alteration during metastatic progression. In the UC-EV cohort, all patients with NECTIN4 amplification (N=14) responded to EV. In multivariable Cox adjusted for age and sex, NECTIN4 amplifications led to a 93% risk reduction for death compared to a NECTIN4non-amplified status (HR=0.07, 95%-CI 0.01–0.53; P<0.001). Conclusions: Our study highlights the value of NECTIN4 amplifications to predict EV responses in patients with mUC. NECTIN4 amplifications occur frequently in different cancer types and therefore have the potential to be a novel tumor-agnostic genomic biomarker that enables tailored NECTIN4-targeted therapies in various entities.

oncology
Biomarkers of Response to Anti-NECTIN4 Antibody-Drug Conjugate Enfortumab Vedotin in Urothelial Cancer

Niklas Klümper,Markus Eckstein

DOI: https://doi.org/10.1016/j.euf.2024.04.001

IF: 5.952

2024-04-18

European Urology Focus

Abstract:Initial studies indicated that NECTIN4 expression is widespread in metastatic urothelial cancer (mUC), which led to approval of the anti-NECTIN4 antibody-drug conjugate (ADC) enfortumab vedotin (EV) for unselected patients with mUC. However, the recent literature suggests that there has been overestimation of membranous NECTIN4 expression in UC, which is a prerequisite for EV binding. It is well established from the development of Her2-targeting ADCs that treatment response is strongly dependent on membranous expression level of the relevant target antigen. In this context, it has been demonstrated that membranous NECTIN4 expression correlates with EV responses and outcomes. Another promising biomarker could be NECTIN4 copy number alteration, a genomic alteration that occurs in approximately 25% of mUC cases, which is associated with strong membranous NECTIN4 expression. Patients with NECTIN4 amplification exhibit an objective response rate of >90% to EV monotherapy and long-term survival. Given the heterogeneous expression of NECTIN4 in UC, future biomarker research is essential for the development of biomarker-driven mUC treatment strategies to further improve outcomes for patients with mUC. Patient summary We reviewed current evidence on biomarkers for predicting response to enfortumab vedotin (EV) treatment for metastatic urinary tract cancer (mUC). Studies to date have shown that patients with high levels of the protein NECTIN4 on their cancer cells respond well to EV. This information has the potential to guide future treatment strategies for mUC.

urology & nephrology
Nectin‐4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin

Woo Cheal Cho,Rayan Saade,Priyadharsini Nagarajan,Phyu P. Aung,Denái R. Milton,Mario L. Marques‐Piubelli,Courtney Hudgens,Debora Ledesma,Kelly Nelson,Doina Ivan,Miao Zhang,Carlos A. Torres‐Cabala,Matthew Campbell,Omar Alhalabi,Victor G. Prieto,Ignacio I. Wistuba,Bita Esmaeli,Jonathan L. Curry

DOI: https://doi.org/10.1111/cup.14579

2024-01-12

Journal of Cutaneous Pathology

Abstract:Background Enfortumab vedotin (EV) is an antibody‐drug conjugate directed against Nectin‐4 that is used to treat urothelial carcinoma. Nectin‐4 is inherently expressed in the skin and adnexal structures. Since therapeutic options for cutaneous adnexal carcinomas are limited, we sought to evaluate Nectin‐4 expression in adnexal carcinomas and benign adnexal neoplasms to identify tumors that are potentially targetable with EV. Methods Eight sebaceous carcinomas (seven periocular and one lymph node metastasis), eight digital papillary adenocarcinomas, seven squamoid eccrine ductal carcinomas, eight poromas, eight trichilemmomas, and seven sebaceous adenomas were subjected to immunohistochemical staining for anti‐Nectin‐4 antibody. H‐scores for Nectin‐4 expression were calculated. Results Benign adnexal neoplasms had a significantly lower mean (±SD) Nectin‐4 H‐score (142.6 ± 39.1) than did the adnexal carcinomas (198 ± 90.8; p = 0.006). Nectin‐4 was expressed in 91% (21/23) of adnexal carcinomas. Sebaceous carcinomas frequently exhibited high expression of Nectin‐4 (88% [7/8]), with a mean (±SD) H‐score (258.1 ± 58.4) significantly higher than those for digital papillary adenocarcinomas (197.5 ± 52.5; p = 0.035) and squamoid eccrine ductal carcinomas (131.4 ± 114.1; p = 0.031). Sebaceous carcinomas also had significantly higher H‐scores than did sebaceous adenomas (186.4 ± 25.0; p = 0.013). Conclusions Increased Nectin‐4 expression in a subset of cutaneous adnexal carcinomas, particularly sebaceous carcinomas, reveals that EV is a potential therapeutic option for these tumors.

dermatology,pathology
The effect of dietary protein on the mineral status of vervet monkeys with special reference to the impact of milk solids on calcium excretion

Q. Johnson,W. Veith,J. Aalbers

DOI: https://doi.org/10.1111/j.1600-0684.1999.tb00282.x

1999-12-01

Journal of Medical Primatology

Abstract:Abstract: This study assessed the impact of Westernised and traditional African diets on mineral metabolism in general and calcium status in particular in vervet monkeys. Twelve adult male vervet monkeys (Cercopithecus aethiops), with an average weight of 5 ± 0.58 kg each, were divided into two groups of six individuals each and fed traditional diets containing largely maize + legumes (17.4%) or Westernised diets containing milk solids (17.2%) as the source of high crude protein for 8 weeks. Blood was taken at 2‐week intervals, the animals were weighed, while urine and stool samples were collected over 24 hours. The monkeys on the milk solids diet had diarrhoea for 6 weeks post‐dietary intervention, and produced significantly greater quantities (P < 0.02) of stool. These animals also produced significantly more urine (P < 0.02). There was no difference in the degree of calciuresis of the two groups, but the monkeys on maize + legume proteins absorbed significantly more calcium during weeks two and six (P < 0.04). Furthermore, both groups of monkeys showed a significant decline in plasma calcium levels over the experimental period (P < 0.001). The diets had no effect on phosphate levels in the plasma or urine. However, both groups of animals absorbed less phosphate (P < 0.09). There was an increasing loss of urinary magnesium (P = 0.03) in both groups, with the milk solids group showing lower plasma levels of this element (P = 0.09). However, the milk solids group lost less magnesium through the stool (P < 0.03). In addition, the animals on milk solids showed significant natriuresis (P < 0.05), while plasma sodium levels in both groups declined over time (P < 0.03). Both diets induced a state of urinary potassium loss (P = 0.0003) and decrease in plasma potassium (P < 0.0002). Urinary pH and plasma urea were unaffected by the diets, but the monkeys on maize + legumes excreted significantly less (P < 0.001) urinary urea. This study indicates that the milk solids diet compromised mineral homeostasis by interfering with gut and renal functioning, while the traditional African diet did not induce these effects.
Immunohistochemical expression of OCT4 and CD44 in major and minor salivary gland neoplasms

Jamile Marinho Bezerra de Oliveira Moura,Amanda Katarinny Goes Gonzaga,Salomão Israel Monteiro Lourenço Queiroz,Manoela Domingues Martins,Leão Pereira Pinto,Lélia Batista de Souza

DOI: https://doi.org/10.1590/1807-3107bor-2021.vol35.0073

2021-06-16

Abstract:The aim of this study was to identify tumor parenchyma cells exhibiting immunohistochemical profile of stem cells by evaluating the immunoreactivity of OCT4 and CD44 in a number of cases of salivary gland neoplasms. The sample consisted of 20 pleomorphic adenomas, 20 mucoepidermoid carcinomas, and 20 adenoid cystic carcinomas located in major and minor salivary glands. The expression of OCT4 and CD44 was evaluated by the percentage of positive cells and the intensity of expression. All studied cases showed positive expression of OCT4 and CD44 and higher values than the control groups. For OCT4, luminal and non-luminal cells were immunostained in the case of pleomorphic adenomas and adenoid cystic carcinomas. Moreover, the immunoreactivity of CD44 was particularly evident in the non-luminal cells of these lesions. In mucoepidermoid carcinomas, there was immunoreactivity for both markers in squamous and intermediate cells and absence of staining in mucous cells. For both markers, a significantly higher immunostaining was verified in neoplasms located in the major salivary glands compared with lesions in minor salivary glands (p<0.001). In the total sample and in minor salivary glands, malignant neoplasms exhibited higher immunoreactivity for OCT4 than pleomorphic adenoma. A significant moderate positive correlation (r = 0.444 and p ≤ 0.001) was found between OCT4 and CD44 immunoexpression in the total sample. The high expression of OCT4 and CD44 may indicate that these proteins play an important role in identifying tumor stem cells.
Therapeutic prospects of nectin-4 in cancer: applications and value

Kaiyue Li,Yujing Zhou,Maolin Zang,Xin Jin,Xin Li

DOI: https://doi.org/10.3389/fonc.2024.1354543

IF: 4.7

2024-03-29

Frontiers in Oncology

Abstract:Nectin-4 is a Ca 2+ -independent immunoglobulin-like protein that exhibits significantly elevated expression in malignant tumors while maintaining extremely low levels in healthy adult tissues. In recent years, overexpression of Nectin-4 has been implicated in tumor occurrence and development of various cancers, including breast cancer, urothelial cancer, and lung cancer. In 2019, the Food and Drug Administration approved enfortumab vedotin, the first antibody–drug conjugate targeting Nectin-4, for the treatment of urothelial carcinoma. This has emphasized the value of Nectin-4 in tumor targeted therapy and promoted the implementation of more clinical trials of enfortumab vedotin. In addition, many new drugs targeting Nectin-4 for the treatment of malignant tumors have entered clinical trials, with the aim of exploring potential new indications. However, the exact mechanisms by which Nectin-4 affects tumorigenesis and progression are still unclear, and the emergence of drug resistance and treatment-related adverse reactions poses challenges. This article reviews the diagnostic potential, prognostic significance, and molecular role of Nectin-4 in tumors, with a focus on clinical trials in the field of Nectin-4-related tumor treatment and the development of new drugs targeting Nectin-4.

oncology
Expression of Cancer Cell-Derived IgG and Extra Domain A-containing Fibronectin in Salivary Adenoid Cystic Carcinoma.

Wan-Qi Lv,Jing Peng,Hai-Cheng Wang,De-ping Chen,Yue Yang,Yang Zhao,Xiao-yan Qiu,Jiu-Hui Jiang,Cui-Ying Li

DOI: https://doi.org/10.1016/j.archoralbio.2017.04.010

IF: 2.64

2017-01-01

Archives of Oral Biology

Abstract:Objective: Cancer-IgG is a newly-discovered molecule, mainly derived from epithelial carcinoma cells and is significantly correlated with differentiation, metastasis, local invasion, and poor prognosis of many cancers. In our previous study we detected IgG expression in oral epithelial carcinoma, including salivary adenoid cystic carcinoma (SACC), using an IgG-specific commercial antibody. Here, we explored the correlation between cancer-IgG and clinicopathological features of SACC.Design: A total of 68 human SACC tissue specimens and 2 siRNAs were used to analyze the correlation between cancer-IgG and extra domain A (EDA(+))-containing fibronectin using the cancer-IgG-specific monoclonal antibody, RP215.Results: We found an unexpected correlation between cancer-IgG and EDA(+) fibronectin, both of which showed aberrant expression in SACC tissue samples. Both were highly expressed in SACC with nerve invasion. In our previous study, EDA(+) fibronectin overexpression in SACC cells decreased N-cadherin expression. In the present study, we used SACC-83 cells, wherein EDA(+) fibronectin is overexpressed and cancer-IgG is knocked down. EDA(+) fibronectin expression was reduced with cancer-IgG knockdown, while cancer-IgG expression did not affect EDA(+) fibronectin overexpression. Furthermore, knockdown of non-B cell-derived IgG in SACC cells decreased cellular motility (P < 0.05) as well as increased E-cadherin and alpha-smooth muscle actin levels.Conclusion: The results suggest that cancer IgG potentially regulates EDA(+) fibronectin, expression, thereby suggesting possible new therapeutic approaches for SACC.
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models

Pia M Challita-Eid,Daulet Satpayev,Peng Yang,Zili An,Karen Morrison,Yuriy Shostak,Arthur Raitano,Rossana Nadell,Wendy Liu,Dawn Ratay Lortie,Linnette Capo,Alla Verlinsky,Monica Leavitt,Faisal Malik,Hector Aviña,Claudia I Guevara,Nick Dinh,Sher Karki,Banmeet S Anand,Daniel S Pereira,Ingrid B J Joseph,Fernando Doñate,Kendall Morrison,David R Stover

DOI: https://doi.org/10.1158/0008-5472.CAN-15-1313

2016-05-15

Abstract:The identification of optimal target antigens on tumor cells is central to the advancement of new antibody-based cancer therapies. We performed suppression subtractive hybridization and identified nectin-4 (PVRL4), a type I transmembrane protein and member of a family of related immunoglobulin-like adhesion molecules, as a potential target in epithelial cancers. We conducted immunohistochemical analysis of 2,394 patient specimens from bladder, breast, lung, pancreatic, ovarian, head/neck, and esophageal tumors and found that 69% of all specimens stained positive for nectin-4. Moderate to strong staining was especially observed in 60% of bladder and 53% of breast tumor specimens, whereas the expression of nectin-4 in normal tissue was more limited. We generated a novel antibody-drug conjugate (ADC) enfortumab vedotin comprising the human anti-nectin-4 antibody conjugated to the highly potent microtubule-disrupting agent MMAE. Hybridoma (AGS-22M6E) and CHO (ASG-22CE) versions of enfortumab vedotin (also known as ASG-22ME) ADC were able to bind to cell surface-expressed nectin-4 with high affinity and induced cell death in vitro in a dose-dependent manner. Treatment of mouse xenograft models of human breast, bladder, pancreatic, and lung cancers with enfortumab vedotin significantly inhibited the growth of all four tumor types and resulted in tumor regression of breast and bladder xenografts. Overall, these findings validate nectin-4 as an attractive therapeutic target in multiple solid tumors and support further clinical development, investigation, and application of nectin-4-targeting ADCs. Cancer Res; 76(10); 3003-13. ©2016 AACR.
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer

Niklas Klümper,Ngoc Khanh Tran,Stefanie Zschäbitz,Oliver Hahn,Thomas Büttner,Florian Roghmann,Christian Bolenz,Friedemann Zengerling,Constantin Schwab,Dora Nagy,Marieta Toma,Glen Kristiansen,Hendrik Heers,Philipp Ivanyi,Günter Niegisch,Camilla Marisa Grunewald,Christopher Darr,Arian Farid,Katrin Schlack,Mahmoud Abbas,Can Aydogdu,Jozefina Casuscelli,Theresa Mokry,Michael Mayr,Dora Niedersüß-Beke,Steffen Rausch,Dimo Dietrich,Jonas Saal,Jörg Ellinger,Manuel Ritter,Abdullah Alajati,Christoph Kuppe,Joshua Meeks,Francisco E. Vera Badillo,J. Alberto Nakauma-González,Joost Boormans,Kerstin Junker,Arndt Hartmann,Viktor Grünwald,Michael Hölzel,Markus Eckstein

DOI: https://doi.org/10.1200/jco.23.01983

IF: 45.3

2024-04-26

Journal of Clinical Oncology

Abstract:PURPOSE The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet uncharacterized patient subset. NECTIN4 is located on chromosome 1q23.3, and 1q23.3 gains represent frequent copy number variations (CNVs) in urothelial cancer. Here, we aimed to evaluate NECTIN4 amplifications as a genomic biomarker to predict EV response in patients with mUC. MATERIALS AND METHODS We established a NECTIN4-specific fluorescence in situ hybridization (FISH) assay to assess the predictive value of NECTIN4 CNVs in a multicenter EV-treated mUC patient cohort (mUC-EV, n = 108). CNVs were correlated with membranous NECTIN4 protein expression, EV treatment responses, and outcomes. We also assessed the prognostic value of NECTIN4 CNVs measured in metastatic biopsies of non–EV-treated mUC (mUC-non-EV, n = 103). Furthermore, we queried The Cancer Genome Atlas (TCGA) data sets (10,712 patients across 32 cancer types) for NECTIN4 CNVs. RESULTS NECTIN4 amplifications are frequent genomic events in muscle-invasive bladder cancer (TCGA bladder cancer data set: approximately 17%) and mUC (approximately 26% in our mUC cohorts). In mUC-EV, NECTIN4 amplification represents a stable genomic alteration during metastatic progression and associates with enhanced membranous NECTIN4 protein expression. Ninety-six percent (27 of 28) of patients with NECTIN4 amplifications demonstrated objective responses to EV compared with 32% (24 of 74) in the nonamplified subgroup ( P < .001). In multivariable Cox analysis adjusted for age, sex, and Bellmunt risk factors, NECTIN4 amplifications led to a 92% risk reduction for death (hazard ratio, 0.08 [95% CI, 0.02 to 0.34]; P < .001). In the mUC-non-EV, NECTIN4 amplifications were not associated with outcomes. TCGA Pan-Cancer analysis demonstrated that NECTIN4 amplifications occur frequently in other cancers, for example, in 5%-10% of breast and lung cancers. CONCLUSION NECTIN4 amplifications are genomic predictors of EV responses and long-term survival in patients with mUC.

oncology
Involvement of Non-B Cell-Derived Immunoglobulin G in the Metastasis and Prognosis of Salivary Adenoid Cystic Carcinoma.

Jing Peng,Hai-Cheng Wang,Yang Liu,Jiu-Hui Jiang,Wan-Qi Lv,Yue Yang,Cui-Ying Li,Xiao-Yan Qiu

DOI: https://doi.org/10.3892/ol.2017.6782

2017-01-01

Oncology Letters

Abstract:Cancer cell-derived immunoglobulin G (cancer-IgG) has been implicated in the pathogenesis and progression of various types of cancer. However, its role in salivary adenoid cystic carcinoma (SACC) remains unclear. The present study aimed to investigate the effects of cancer-IgG on metastasis and prognosis in 96 patients with SACC. Immunohistochemical staining showed that cancer-IgG expression was present in all 96 individual SACC tissues. Additionally, high cancer-IgG expression was significantly correlated with metastasis, nerve invasion and recurrence in SACC (P<0.05). Moreover, cancer-IgG expression was significantly correlated with the survival duration of patients with SACC (P<0.05). Proliferation, cell motility and invasion all decreased significantly following knockdown of cancer-IgG in SACC cells (P<0.05) through population-doubling time, wound healing and transwell invasion assays. Additionally, cancer-IgG-knockdown in SACC cells induced the increased expression of E-cadherin and matrix metalloproteinase 9, and promoted the epithelial-mesenchymal transition, but decreased the expression of F-actin filaments. Taken together, these results showed that the high expression of cancer-IgG was strongly associated with metastasis, recurrence and invasion in SACC, suggesting that cancer-IgG expression could serve as a useful biomarker to predict the prognosis of the disease.
Anatomic Extent of Lymph Node Metastases As an Independent Prognosticator in Node-Positive Major Salivary Gland Carcinoma: A Study of the US SEER Database and a Chinese Multicenter Cohort.

Xiao Shi,Xue-Kui Liu,Chang-Ming An,Wen-Jun Wei,Yungan Tao,Yuan Ji,Yan Zhang,Wei Han,Jin-Cai Xue,Nai-Si Huang,Ben Ma,Chen-Ping Zhang,Xi Yang,Ke-Jing Wang,Qin-Jiang Liu,Yang Liu,Yu Wang,Bo-Wen Lei,Peng-Cheng Yu,Jia-Qian Hu,Zhong-Wu Lu,Wei-Ping Hu,You-Xin Tian,Yu-Long Wang,Qing-Hai Ji

DOI: https://doi.org/10.1016/j.ejso.2019.06.029

IF: 4.037

2019-01-01

European Journal of Surgical Oncology

Abstract:BACKGROUND:We aimed to explore whether the anatomic extent of lymph node metastases (AE-LNM) could independently predict prognosis of node-positive major salivary gland carcinoma (MaSGC).METHODS:A total of 376 pathologically node-positive MaSGC patients were identified from the Surveillance, Epidemiology and End Results database and constituted the training cohort. Using the X-Tile program, these patients were divided into three groups based on AE-LNM degrees. Discrimination of overall survival (OS) and disease-specific survival (DSS) was evaluated and compared with the 8th American Joint Committee on Cancer (AJCC) pN classification. The results were externally validated by 220 patients in a Chinese multicenter cohort (Validation cohort).RESULTS:Using the training cohort, AE-LNM was divided into Extent 1 (spread to parotid LNs or level I), Extent 2 (spread to level II-IV) and Extent 3 (spread to level V or bilateral LNs or rare LNs). Regarding both OS and DSS, the AE-LNM model revealed clear separation of survival curves, while the pN classification failed to discriminate the prognosis of pN1 and pN2 patients. When we incorporated both the AE-LNM model and AJCC pN classification into the same multivariate Cox analyses, AE-LNM was still an independent prognostic factor, while the AJCC pN classification lost its significance. These results were externally validated by the validation cohort.CONCLUSION:AE-LNM is an independent nodal prognosticator for node-positive MaSGC and may have improved discriminative ability over the current AJCC pN classification. Integration of anatomic extent of LNM into the current AJCC N classification could be considered.

Intolerance to additives.

Transient segmental asynergy of the left ventricle of patients with various clinical manifestations possibly unrelated to the coronary artery disease.

Nectin-4 expression in primary breast cancer and associated clinical outcomes.

Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes

Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas

Nectin-4: A promising prognostic marker and therapeutic target in cancer

Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate

Pneumovesicoscopic Correction of Primary Vesicoureteral Reflux (VUR) in Children. Our Experience

Targeted Therapeutic Strategies for Nectin-4 in Breast Cancer: Recent Advances and Future Prospects

Expression of Neural Cell Adhesion Molecule in 49 Cases with Salivary Adenoid Cystic Carcinoma and Its Significance

Occurrence of NECTIN4 amplification in solid tumors and enfortumab vedotin response in metastatic urothelial cancer.

Biomarkers of Response to Anti-NECTIN4 Antibody-Drug Conjugate Enfortumab Vedotin in Urothelial Cancer

Nectin‐4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin

The effect of dietary protein on the mineral status of vervet monkeys with special reference to the impact of milk solids on calcium excretion

Immunohistochemical expression of OCT4 and CD44 in major and minor salivary gland neoplasms

Therapeutic prospects of nectin-4 in cancer: applications and value

Expression of Cancer Cell-Derived IgG and Extra Domain A-containing Fibronectin in Salivary Adenoid Cystic Carcinoma.

Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models

NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer

Involvement of Non-B Cell-Derived Immunoglobulin G in the Metastasis and Prognosis of Salivary Adenoid Cystic Carcinoma.

Anatomic Extent of Lymph Node Metastases As an Independent Prognosticator in Node-Positive Major Salivary Gland Carcinoma: A Study of the US SEER Database and a Chinese Multicenter Cohort.